studies

780A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Disclosures:
Robert Gish - Advisory Committees or Review Panels: Gilead, AbbVie, Arrowhead;
Consulting: Eiger, Isis, Genentech; Speaking and Teaching: Gilead, Abb-
Vie; Stock Shareholder: Arrowhead
Richard A. Manch - Speaking and Teaching: Gilead, AbbVie, Bayer, Salix, BMS
The following authors have nothing to disclose: Shruti Mony, Shirin Nafisi, Justin
A. Reynolds, Ann Moore, Ashley Hepner, Karen Arendt, Yvette Cummings, Anita
Kohli
1156
Sofosbuvir-based treatments for patients with hepatitis
C virus (HCV) mono-infection and human immunodeficiency
virus (HIV)-HCV co-infection with genotype 1 and
4 in clinical practice – Results from the GErman hepatitis
C COhort (GECCO)
Stefan Mauss 1 , Knud Schewe 2 , Jürgen K. Rockstroh 3 , Dietrich
Hueppe 4 , Axel Baumgarten 5 , Guenther Schmutz 1 , Karl-Georg
Simon 6 , Thomas Lutz 8 , Heiner W. Busch 7 , Patrick Ingiliz 5 , Stefan
Christensen 7 ; 1 Center for HIV and Hepatogastroenterology,
Duesseldorf, Germany; 2 ICH, Hamburg, Germany; 3 Department I
University Hospital Bonn, Bonn, Germany; 4 Center for Gastroenerology,
Herne, Germany; 5 MIB, Berlin, Germany; 6 Practice for
Gastroenterology, Leverkusen, Germany; 7 CIM, Muenster, Germany;
8 Infektiologikum, Frankfurt, Germany
Introduction: The first direct acting antivirals (DAA) were
approved in Europe in 2014 based on limited study data.
In particular, HIV-HCV co-infected patients and pre-treated
patients had not been systematically studied. Here, we present
real-life data on efficacy and safety of sofosbuvir (SOF)-based
therapies from Germany. Methods: In this multicenter cohort,
patients who were started on sofosbuvir-based treatments were
documented consecutively. For the current analysis, patients
included had HCV genotype 1 and 4 treated with: SOF/
PegIFN/RBV (ribavirin) 12 weeks, SOF/DCV (daclatasvir)
12/24 weeks, SOF/SMV (simeprevir) 12 weeks and SOF/LDV
(ledipasvir) 8/12 weeks. Patients within the GECCO cohort
are part of the prospective German hepatitis C registry. Results:
Overall, 836 patients on SOF-containing regimens have been
enrolled so far. Of those, 629 (75%) are HCV-monoinfected
and 207 (25%) HIV-HCV co-infected. 536 patients (60%) were
male, the median age was 52 years. 421 patients (52%) had
been pretreated, mainly with PegIFN and RBV. Liver cirrhosis
was reported in 217 patients (27%), in the majority of cases
(71%) defined by a transient elastography value (Fibroscan®)
>12.5kPa. 17/217 (8%) cirrhotic patients had Child-Pugh
stage B or C. HCV genotype 1 was present in 584 patients
(69%), and genotype 4 in 48 patients (6%). Most HIV-HCV
co-infected patients (205/207) were on antiretroviral therapy
and had HIV-RNA 2) were less likely to achieve
SVR12 compared to non-cirrhotic patients (APRI